Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle.
Rapafusyn Pharmaceuticals has raised $16.0M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Rapafusyn Pharmaceuticals's investors include 3E Bioventures, Lapam Capital, BioTrack Capital, Prox Ventures, Yonjin Venture.
Rapafusyn Pharmaceuticals is headquartered in Baltimore, United States.
Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle.
Rapafusyn Pharmaceuticals is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rapafusyn Pharmaceuticals — Funding & Investors." VCBacked, September 4, 2025, https://www.vcbacked.co/company/rapafusyn-pharmaceuticals. Accessed October 1, 2026.
VCBacked. (2025). Rapafusyn Pharmaceuticals — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/rapafusyn-pharmaceuticals
{{cite web |title=Rapafusyn Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/rapafusyn-pharmaceuticals |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated